Enovis Corporation reported a net loss of $1.18 billion for the fiscal year ending December 31, 2025, a significant increase from a loss of $824.8 million in the previous year. The company's total revenue for 2025 reached $2.25 billion, reflecting a 6.7% increase from $2.11 billion in 2024. This growth was primarily driven by a rise in sales from existing businesses and contributions from recent acquisitions, including the notable acquisition of LimaCorporate S.p.A. in January 2024, which expanded Enovis's product offerings in the reconstructive segment.
The company experienced a substantial goodwill impairment charge of $1.05 billion in 2025, attributed to a sustained decline in its stock price and market capitalization. This impairment followed a previous charge of $645 million in 2024. The total accumulated goodwill impairment loss now stands at $1.69 billion, indicating ongoing challenges in maintaining asset valuations amid market fluctuations. Despite these setbacks, Enovis reported an adjusted EBITDA of $403 million for 2025, up from $376.5 million in 2024, highlighting operational improvements and cost management efforts.
Strategically, Enovis completed several acquisitions in 2025, totaling approximately $36.9 million, which included two businesses in the Prevention & Recovery segment and three distributors in the Reconstructive segment. The company also divested its Dr Comfort Footcare Solutions product line for up to $60 million, which included an upfront payment of $45 million. These strategic moves are part of Enovis's broader growth strategy, which aims to enhance its market presence and product offerings across various geographic regions, particularly in Europe and the Asia-Pacific.
Operationally, Enovis reported that approximately 42% of its sales were derived from international operations, with a significant portion coming from Europe. The company has focused on expanding its global footprint and enhancing its distribution capabilities. As of December 31, 2025, Enovis employed approximately 7,802 individuals, with a notable increase in research and development spending aimed at driving innovation in its product lines. The company anticipates continued growth in 2026, supported by its strategic acquisitions and a commitment to improving patient outcomes through advanced medical technologies.
Looking ahead, Enovis remains focused on leveraging its Enovis Growth Excellence (EGX) business system to drive operational efficiencies and enhance customer value. The company is also navigating challenges related to inflationary pressures and supply chain disruptions, which may impact future profitability. Enovis's management is optimistic about the potential for recovery and growth, particularly as it integrates recent acquisitions and expands its product offerings in the competitive medical technology landscape.
About Enovis CORP
Enovis Corporation is a medical technology company specializing in developing and distributing high-quality medical devices for reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention to recovery, serving healthcare professionals and consumers worldwide. The company emphasizes innovation, quality, and continuous improvement through its EGX management system, competing with leading global brands in fragmented, highly regulated markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.